The efficacy of combination immunotherapy with ipilimumab plus nivolumab in metastatic myxofibrosarcoma

Foteini Kalofonou1, Andrea Napolitano1, Charlotte Benson1

  • 1Sarcoma Unit, The Royal Marsden Hospital and Institute of Cancer Research, London, UK.

Rare Tumors
|November 8, 2024
PubMed

We present the case of a patient with Myxofibrosarcoma (MFS), a mesenchymal type of soft tissue sarcoma (STS) and the response to combination immunotherapy with anti PD-1 and anti-CTLA-4 therapy, following disease progression after Standard chemotherapy (SACT) and Radiotherapy (RT). We have shown a timeline of treatment and responses, as well as the overall safety profile and the management of immunotherapy related adverse events. This study demonstrates the potential of checkpoint inhibitors as therapeutic agents in the treatment of MFS.

Related Concept Videos